Biotech Values

[DFRAI]

BSR_David

The chief worry on the ONCY trial is not the adaptive design. It is the fact they entered a combination Phase III with zero randomized experience with the combination in this disease and very few patients at all treated with this combination in this disease stage.

I dont quite understand your statement above. Randomized experience - does one need experience to administer the same drug to different patients?

I think its a question of how comfortable you are that your drug works and it seemed to them that it may work best in this type of cancer (maybe too simplistic)

Thanks for the adaptive explanation